Fertility and Sterility · 2017 · 80 citations · 26 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyEndocrine PharmacotherapyWomen's Health PharmacotherapyMenopause Hormone TherapyMenopause PharmacotherapyReproductive Endocrine PharmacotherapyReproductive Endocrinology PharmacotherapySide EffectsUterine Fibroid PharmacotherapyAdd-on TherapyDose-dependent TolerabilityHeavy Menstrual Bleeding ManagementIrregular Menstrual Bleeding ManagementMenstrual Bleeding ControlMenstrual Bleeding PatternsPharmacologic Therapy For FibroidsSerious Adverse Events
Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-dose E 2 /progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple-cohort study. Setting Clinics. Patient(s) Premenopausal women with fibroids and heavy menstrual bleeding (menstrual blood loss [MBL] >80 mL per cycle). Intervention(s) Three months' treatment with elagolix alone: 100 mg twice daily (BID), 200 mg BID, 300 mg BID, 400 mg once daily (QD), or 600 mg QD (all but the 600 mg QD arm were placebo controlled); or elagolix plus add-back therapy: 200 mg BID plus continuous low-dose E 2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E 2 1 mg continuously and cyclical P 200 mg. Main Outcome Measure(s) Least-squares mean percentage change in MBL; adverse events (AEs). Result(s) Mean age was 41.8 years; 73.8% were black; mean baseline MBL was 267 mL. Of randomized women (elagolix alone, n=160; placebo, n=50; elagolix with add-back therapy, n=61), 228 of 271 completed the 3-month treatment period. The MBL percentage change from baseline to last 28 days was significantly greater with elagolix alone (range, −72% to −98%; dose-dependent reduction was highest with 300 mg BID) vs. placebo (range, −8% to −41%); mean percentage changes with add-back regimens were −80% to −85%. Overall AEs were dose independent (elagolix alone, 70.0%–81.3%) but lower with placebo (56.0%) and add-back regimens (55.6%–70.6%). Hot flush was the most common AE (elagolix alone, 45.5%–62.5%; placebo, 12.0%; add-back regimens, 18.5%–26.5%). Conclusion(s) Elagolix significantly reduced heavy menstrual bleeding in women with fibroids. Low-dose add-back regimens substantially reduced flushing. Clinical Trial Registration Number NCT01441635.
26
Menstrual Blood Loss–A Population Study
Leif Hallberg, Ann‐Marie Hôgdahl, Lennart Nilsson et al. · Acta Obstetricia Et Gynecologica Scandinavica · 1966 · 974 citations
Medicine, Gynecology, Obstetrics +14
Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States
Jason D. Wright, Thomas J. Herzog, Jennifer Tsui et al. · Obstetrics and Gynecology · 2013 · 761 citations · Full text
Medicine, Gynecology, Surgery +3
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Jacques Donnez, Philippe Bouchard, Lucian Pușcașiu et al. · New England Journal of Medicine · 2012 · 677 citations · Full text